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Breast cancer care delivery is known to be uneven in the
United States [1]. Clinicians and researchers have long
observed differences in the process and outcomes of care
for women diagnosed with breast cancer that can be
attributed to observable individual and societal character-
istics [2–6]. Researchers have reported noteworthy differ-
ences in screening, diagnosis, treatment, and mortality by
age, race, ethnicity, geographic location, education, and
income. It is important to recognize there are contradictory
findings in the literature, specifically regarding the rela-
tionship between race/ethnicity and quality of chemother-
apy care. The seminal Institute of Medicine report Unequal
Treatment recognized these differences and the broader
impact of disparities in health care delivery on the nation’s
health [7]. The report’s authors noted the complexity in
both understanding and remedying the current state. A
persistent challenge to correcting disparities in breast
cancer care delivery is the limited understanding of the
reasons for the observed disparities [8].
Currently, we have a problem of uncertain size, scope,
and etiology. Research studies that include triangulated
data across sources, such as cancer registries, clinical
registries, and surveys of patients and providers, will help
disentangle current confusion and stimulate evidence-based
quality improvement and policy efforts. In this context, the
paper by Lipscomb et al. in this issue of Breast Cancer
Research and Treatment is a necessary piece to solve this
complex puzzle. A key contribution from this paper is that
the findings stem from a unique combination of cancer
registry data and clinical records. The authors used the
Georgia Comprehensive Cancer registry to identify inci-
dent cases of breast cancer and abstracted records on 868
women treated in 27 oncology settings located in relatively
rural Southwest Georgia. These linked data enable us to
understand, at least in part, how several personal charac-
teristics may influence variation in high-quality breast
cancer care.
The authors should be commended for their exhaustive
attention to potentially confounding variables through
sensitivity analyses and examination of interaction effects.
Their careful attention to these issues increases the confi-
dence in the principal study findings. In multivariable
models, they found no differences in chemotherapy initi-
ation by race. However, women who resided in impover-
ished areas were significantly less likely to initiate
chemotherapy. This is an important finding that merits
further attention and discussion. Of all the women in the
study who initiated chemotherapy, 10% did not complete
their originally intended plan, primarily due to toxicity. In
a multivariable model that included interaction terms
between race and marital status and race and comorbidity,
unmarried black women had higher likelihood of chemo-
therapy completion compared with unmarried white
women. Unmarried women with comorbid conditions were
less likely to complete chemotherapy than unmarried
women without comorbid conditions. Differences in che-
motherapy initiation and completion were negligible for
married women in the sample. One way to interpret these
interesting findings is through the lens of social support.
Marital status may serve as a proxy for the larger con-
cept of social support, which may influence treatment
decisions and outcomes. While social support was not
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measured directly in this study, the presence of social
support has been shown to benefit women with breast
cancer [9, 10]. Researchers have struggled to understand
whether the quantity (i.e., number of people who provide
support) or quality (strength of the support provided) is
important [11]. A key takeaway for clinicians is to put
systems in place to assess patients for both the quantity and
quality of social support available to them. For patients
with social support that is low in quantity, quality, or both,
targeted interventions may prove beneficial. Context is also
important: the authors reported that a transportation ini-
tiative, expanded insurance coverage, and other social
programs were present in this community at the time of the
study although it is not clear which patients participated.
Strong social networks through churches or civic groups
may serve as important advocates for women during
treatment or help patients advocate for themselves. The
expanding role of breast cancer navigators was not
addressed in the study although the literature is equivocal
on the efficacy of these heterogeneous programs.
Some secondary findings merit further discussion: che-
motherapy initiation rates for clinically eligible patients
varied significantly across the four identified treatment
sites that were Commission on Cancer-accredited and the
fifth category of 23 unaffiliated or free-standing practices,
with a range of 21.2–47.7%. Rates of planned chemother-
apy completion varied significantly across practice as well
(range of 83.3–100%). This reflects the under-recognized
and -studied problem of practice variation in medical
oncology settings. The National Cancer Policy Board
identified the absence of a robust data platform for quality
data reporting and improvement as a key challenge to
improved cancer care quality [12]. One wonders if the
practices unaffiliated with the Commission on Cancer
knew their chemotherapy initiation and completion rates
for this curable disease. Without such data, how can
practices implement quality improvement? Moreover, the
requisite data to study cancer care quality remains far too
fragmented; researchers are compelled to re-invent the
wheel and forge complex partnerships to obtain necessary
data for each new study. The Surveillance, Epidemiology,
and End-Results program at the National Cancer Institute
with the available linkage to Medicare files is an important
asset to studying the problem. However, tumor registry and
claims data are not sufficient to understand the complex
interactions between patients and providers. Until we are
able to triangulate data sources—cancer registries, clinical
practice records, and surveys of providers of patients—in a
reliable and robust way, the goal to measure and improve
the quality of cancer care delivery in the United States will
remain elusive.
The article by Lipscomb et al., contributes several pie-
ces to our as yet-incomplete puzzle of how disparities
influence the process and outcome of breast cancer therapy.
First, we are able to explain in part how relationships
between race/ethnicity and health care delivery may be
more complicated than conventional wisdom suggests.
Second, a wider view of social support may be a useful lens
from which to examine disparities in future research.
Finally, additional data suggest noteworthy practice-level
variation in the delivery in chemotherapy care.
The findings suggest we have work ahead of us as a
community of clinicians and scholars devoted to improving
care for women with breast cancer. First, we must create
structures that enable clinicians and researchers to share
data to better understand the problem. We should measure
the quantity and quality of social support that our patients
have during their cancer experience. For those women who
are considered vulnerable to poor outcomes, whether due to
race, income, comorbidity, low social support, or other
factors, we need to develop interventions that support them
through their care experience. These strategies will help
reduce the unwanted variation in breast cancer delivery and
optimize outcomes for our patients.
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